News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
2,592 Results
Type
Article (210)
Company Profile (2)
Press Release (2380)
Section
Business (868)
Career Advice (5)
Deals (129)
Drug Delivery (3)
Drug Development (299)
Employer Resources (3)
FDA (101)
Job Trends (75)
News (1276)
Policy (115)
Tag
2027 Bio NC Standard (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
Academia (8)
Allergies (6)
Alliances (250)
Alzheimer's disease (3)
Antibody-drug conjugate (ADC) (2)
Approvals (110)
Artificial intelligence (3)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (53)
BIO (2)
Biotechnology (2)
Cancer (5)
Cardiovascular disease (4)
Career advice (3)
CDMO (3)
Cell therapy (5)
Clinical research (247)
Collaboration (13)
COVID-19 (24)
C-suite (8)
Cystic fibrosis (6)
Data (25)
Diabetes (2)
Diagnostics (22)
Drug discovery (1)
Drug pricing (5)
Duchenne muscular dystrophy (1)
Earnings (252)
Editorial (1)
Employer branding (1)
Employer resources (3)
Events (287)
Executive appointments (4)
FDA (124)
Funding (8)
Gene editing (2)
Gene therapy (10)
GLP-1 (4)
Government (25)
Guidances (6)
Healthcare (58)
IgA nephropathy (6)
Immunology and inflammation (1)
Infectious disease (33)
Influenza (8)
Intellectual property (1)
Interviews (1)
IPO (45)
Job creations (13)
Job search strategy (3)
JPM (2)
Labor market (3)
Layoffs (7)
Legal (10)
Lung cancer (1)
Management (1)
Manufacturing (12)
Medical device (24)
Medtech (24)
Mergers & acquisitions (97)
Metabolic disorders (4)
mRNA (7)
Multiple sclerosis (1)
Neuroscience (6)
NextGen: Class of 2026 (23)
Non-profit (10)
Now hiring (19)
Obesity (2)
Parkinson's disease (2)
Patient recruitment (2)
People (275)
Phase 1 (72)
Phase 2 (96)
Phase 3 (121)
Pipeline (49)
Policy (1)
Postmarket research (11)
Preclinical (27)
Prostate cancer (2)
Radiopharmaceuticals (19)
Rare diseases (18)
Real estate (33)
Recruiting (1)
Regulatory (120)
Research institute (9)
Sickle cell disease (1)
Special edition (1)
Startups (12)
Supply chain (3)
Vaccines (17)
Venture capital (1)
Weight loss (1)
Women's health (1)
Date
Last 7 days (1)
Last 30 days (15)
Last 365 days (137)
2026 (102)
2025 (122)
2024 (178)
2023 (145)
2022 (240)
2021 (228)
2020 (247)
2019 (177)
2018 (132)
2017 (136)
2016 (89)
2015 (67)
2014 (66)
2013 (55)
2012 (83)
2011 (67)
2010 (103)
Location
Africa (2)
Asia (205)
Australia (239)
California (102)
Canada (8)
China (4)
Colorado (9)
Connecticut (2)
Delaware (1)
Europe (455)
Florida (7)
Georgia (2)
Illinois (9)
India (2)
Indiana (28)
Japan (5)
Maryland (6)
Massachusetts (43)
Minnesota (1)
New Hampshire (1)
New Jersey (23)
New York (14)
North Carolina (7)
Northern California (15)
Ohio (3)
Pennsylvania (14)
Rhode Island (2)
South America (4)
South Carolina (1)
Southern California (74)
Tennessee (2)
Texas (7)
United States (222)
Utah (1)
Virginia (2)
Washington State (2)
2,592 Results for "csl behring".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
July 27, 2026
·
6 min read
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.
February 18, 2026
·
2 min read
·
Tristan Manalac
Press Releases
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
October 7, 2025
·
7 min read
Press Releases
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada
May 20, 2026
·
10 min read
Layoffs
CSL Overhauls Business With Vaccine Spinout, 15% Layoffs
With its structural changes, CSL expects to generate $500 to $550 million in annualized savings over the next three years.
August 20, 2025
·
1 min read
·
Tristan Manalac
Drug Development
ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112
ABIONYX Pharma acknowledges that the Phase 3 AEGIS-II study evaluating the efficacy and safety of CSL Behring’s human-plasma-derived apoA-I, CSL112, compared to placebo in reducing the risk of major adverse cardiovascular events in patients following an acute myocardial infarction, did not meet its primary efficacy endpoint of MACE reduction at 90 days.
February 15, 2024
·
1 min read
Pharm Country
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
CSL Behring today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid).
January 3, 2024
·
8 min read
Pharm Country
CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
CSL Behring, a business unit of global biotechnology leader CSL, announced the availability of 4- and 5-gram vial sizes for ZEMAIRA®
January 2, 2024
·
4 min read
Layoffs
Q3 Layoffs Up 280% YOY With CSL, Merck, Novo’s Restructurings
Due largely to CSL, Merck and Novo Nordisk’s reorganizations that could total about 19,350 people, Q3 cuts rose significantly year over year and quarter over quarter, based on
BioSpace
tallies.
October 16, 2025
·
4 min read
·
Angela Gabriel
Press Releases
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
December 9, 2024
·
5 min read
1 of 260
Next
